Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021.
Video Reports
Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma
Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.
Dr. Hamid on the Differences in Evaluation Criteria for TIL Therapy in Melanoma
Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes (TIL) therapy in melanoma.
Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma
Jason J. Luke, MD, FACP, director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, associate professor of medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma.